X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
1st-line treatment (1671) 1671
index medicus (1591) 1591
oncology (1561) 1561
humans (1493) 1493
open-label (1337) 1337
chemotherapy (1240) 1240
gefitinib (946) 946
lung neoplasms - drug therapy (841) 841
mutation (788) 788
erlotinib (770) 770
carcinoma, non-small-cell lung - drug therapy (755) 755
female (713) 713
lung cancer (661) 661
cancer (650) 650
lung cancer, non-small cell (604) 604
male (597) 597
lung neoplasms - genetics (566) 566
aged (534) 534
middle aged (531) 531
antineoplastic agents - therapeutic use (509) 509
carcinoma, non-small-cell lung - genetics (481) 481
lung neoplasms - pathology (469) 469
care and treatment (461) 461
epidermal growth factor (460) 460
receptor, epidermal growth factor - genetics (443) 443
growth-factor receptor (442) 442
protein kinase inhibitors - therapeutic use (433) 433
non-small cell lung cancer (426) 426
adenocarcinoma (407) 407
carcinoma, non-small-cell lung - pathology (403) 403
multicenter (398) 398
treatment outcome (395) 395
egfr (388) 388
adult (377) 377
cell lung-cancer (372) 372
respiratory system (361) 361
acquired-resistance (353) 353
tyrosine kinase inhibitors (344) 344
phase-iii trial (323) 323
receptor, epidermal growth factor - antagonists & inhibitors (322) 322
cancer therapies (300) 300
research (292) 292
aged, 80 and over (287) 287
antineoplastic combined chemotherapy protocols - therapeutic use (286) 286
tyrosine (285) 285
phase-iii (279) 279
metastasis (273) 273
tyrosine kinase inhibitor (272) 272
epidermal growth factor receptor (271) 271
genetic aspects (265) 265
hematology, oncology and palliative medicine (260) 260
disease-free survival (258) 258
analysis (257) 257
double-blind (255) 255
nsclc (254) 254
phase-ii trial (254) 254
respiratory tract diseases (251) 251
quinazolines - therapeutic use (246) 246
survival (245) 245
afatinib (244) 244
pharmacology & pharmacy (243) 243
patients (240) 240
1st-line therapy (239) 239
egfr mutations (236) 236
prognosis (236) 236
neoplasm staging (231) 231
lung neoplasms - mortality (227) 227
tumors (227) 227
health aspects (223) 223
egfr mutation (208) 208
bevacizumab (200) 200
drug therapy (199) 199
medicine & public health (194) 194
clinical trials (193) 193
carcinoma, non-small-cell lung - mortality (191) 191
non-small cell lung carcinoma (190) 190
molecular targeted therapy (185) 185
kinases (184) 184
non-small-cell lung cancer (182) 182
epidermal growth factor receptors (175) 175
therapy (175) 175
development and progression (172) 172
targeted therapy (172) 172
mutations (170) 170
erbb receptors - genetics (165) 165
animals (162) 162
cetuximab (160) 160
lung cancer, small cell (157) 157
retrospective studies (156) 156
trial (152) 152
adenocarcinoma - drug therapy (151) 151
carboplatin (151) 151
studies (149) 149
review (147) 147
antineoplastic agents - pharmacology (146) 146
randomized phase-3 trial (141) 141
growth-factor-receptor (139) 139
receptor, epidermal growth factor - metabolism (134) 134
clinical trials as topic (133) 133
survival analysis (128) 128
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2234) 2234
French (15) 15
German (3) 3
Chinese (1) 1
Polish (1) 1
Portuguese (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 947 - 957
This trial compared gefitinib, an inhibitor of the tyrosine kinase of epidermal growth factor (EGFR), with carboplatin plus paclitaxel as initial treatment of... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | FACTOR-RECEPTOR GENE | MULTICENTER | THERAPY | FUNCTIONAL ASSESSMENT | PROSPECTIVE PHASE-II | 1ST-LINE GEFITINIB | EGFR MUTATIONS | TREATED PATIENTS | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Adenocarcinoma - mortality | Care and treatment | Dosage and administration | Nonsmokers | Gefitinib | Health aspects | Lung cancer | Chemotherapy | Pharmaceutical industry | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 139 - 148
Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT... 
CELL LUNG-CANCER | SURVIVAL | FORTHCOMING 7TH EDITION | 1ST-LINE TREATMENT | PLACEBO | ESMO CONSENSUS CONFERENCE | THERAPY | ONCOLOGY | TNM CLASSIFICATION | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Pneumonectomy | Protein Kinase Inhibitors - adverse effects | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | China | Adult | Female | Quinazolines - administration & dosage | Chemotherapy, Adjuvant | Gefitinib | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Quinazolines - adverse effects | Cisplatin - adverse effects | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Vinorelbine | Lung cancer, Non-small cell | Care and treatment
Journal Article
Cancer, ISSN 0008-543X, 06/2018, Volume 124, Issue 11, pp. 2407 - 2414
BACKGROUND This is the first report of long‐term (>10 years) safety, tolerability, and survival data on patients with non–small cell lung cancer (NSCLC) who... 
non–small cell lung cancer | gefitinib | tyrosine kinase inhibitor | epidermal growth factor receptor | safety | progression‐free survival | progression-free survival | non-small cell lung cancer | 1ST-LINE TREATMENT | ADENOCARCINOMA | OPEN-LABEL | EGFR MUTATIONS | BREAST-CANCER | RANDOMIZED PHASE-3 TRIAL | ONCOLOGY | QUALITY-OF-LIFE | NEVER-SMOKERS | RECEPTOR TYROSINE KINASE | PREVIOUSLY TREATED PATIENTS | Lung Neoplasms - drug therapy | United States - epidemiology | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Gefitinib - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Retrospective Studies | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Survival Rate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Survival Analysis | Aged | Gefitinib - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Treatment outcome | Lung cancer, Small cell | Dosage and administration | Gefitinib | Drug therapy | Analysis | Adenocarcinoma | Tyrosine | Therapy | Cell survival | Epidermal growth factor receptors | Lung cancer | Non-small cell lung carcinoma | Patients | Survival | Molecular chains | Demographics | Epidermal growth factor | Safety | Protein-tyrosine kinase | Smoking | Cancer | Tumors
Journal Article
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 2/2009, Volume 20, Issue 2, pp. 298 - 304
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2244 - 2250
PurposeARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naive patients with advanced non-small-cell lung... 
1ST-LINE TREATMENT | CONTROLLED-TRIAL | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | PHASE-3 TRIAL | OPEN-LABEL | AFATINIB | INHIBITOR | CHEMOTHERAPY | ERLOTINIB
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 466 - 475
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 02/2014, Volume 9, Issue 2, pp. 189 - 194
Journal Article